A recent study found that postoperative risks for ulcerative colitis patients taking the drug tofacitinib were comparable to those taking biologics. The study suggests that both treatments have similar safety profiles in terms of postoperative outcomes. This information can help guide treatment decisions for patients with ulcerative colitis. Additionally, the use of cookies on the website is mentioned, with users agreeing to their use by continuing to browse the site. More information on cookie usage can be found in the site’s Cookie Policy and Cookie Settings.
Source link
New Study Reveals Comparable Postoperative Risks of Tofacitinib and Biologics in Ulcerative Colitis Patients
